VX-445-Tezacaftor-Ivacaftor in Cystic Fibrosis
C ystic fibrosis is a rare, progressive, lethal, recessive genetic disease caused by diminished quantity or function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, an epithelial channel that conducts chloride and other anions, as a consequence of mutations in CFTR. In a companion article in the Journal by Davies et al. that examines VX-659, the rationale for triple combination therapy in cystic fibrosis with the use of two CFTR correctors and a potentiator is provided. 1 In this article, we examine the effects of VX-445, another small-molecule corrector that shares some structural similarities and a mechanism of action with VX-659, which is designed to improve Phe508del CFTR protein processing and trafficking. Because VX-445 has a mechanism of action that is different from that of the firstgeneration corrector tezacaftor, we hypothesized that combining VX-445 and tezacaftor would result in a greater amount of Phe508del CFTR protein at the cell surface than would either molecule alone. We also hypothesized that the addition of the CFTR potentiator ivacaftor, which increases CFTR gating activity, would further augment CFTR function. On the basis of substantial efficacy in vitro in primary human bronchial epithelial cells 2 from patients heterozygous for the Phe508del CFTR mutation and a minimalfunction mutation (Phe508del-MF) and those with a homozygous Phe508del genotype (Phe508del-Phe508del), we investigated the effects of VX-445-tezacaftor-ivacaftor triple combination therapy on lung function, CFTR activity, and other outcomes in a phase 2, proof-of-concept trial involving patients with cystic fibrosis with one or two Phe508del alleles. The clinical development of VX-445 and VX-659 was undertaken in parallel to increase the likelihood of securing an approved therapy for this patient population.
Me thods

Trial Oversight
The trial was designed by Vertex Pharmaceuticals in collaboration with the authors. Data gathering and analysis were performed by Vertex in collaboration with the authors and the VX16-445-001 Study Group. All authors had full access to trial data after the data were unblinded and provided critical review of the manuscript. The first draft was written by an author who is employed by Vertex Pharmaceuticals with the assistance of medical writers funded by the sponsor. The investigators vouch for the accuracy and completeness of the data generated at their respective institutions, and the investigators and Vertex vouch for the fidelity of the trial to the protocol. Confidentiality agreements were in place between the sponsor and all investigators during the trial. The trial protocol and statistical analysis plan are available with the full text of this article at NEJM.org.
Preclinical Development
In vitro pharmacologic evaluation of VX-445 was conducted. This evaluation is described in the Methods section in the Supplementary Appendix (available at NEJM.org) and in the accompanying article on VX-659.
1
Clinical Development
After a phase 1 trial involving healthy volunteers (not reported here), a three-part, randomized, double-blind, placebo-or active-controlled, parallelgroup, dose-ranging, phase 2 trial was conducted from July 2017 through March 2018. Patients 18 years of age or older with cystic fibrosis were enrolled at 38 sites in the United States, the Netherlands, Belgium, and Australia. The trial design and conduct were similar to those presented in the companion trial of VX-659 1 (see page 7 in the Supplementary Appendix for details).
Patients with Phe508del-MF genotypes were randomly assigned to receive 4 weeks of active treatment -with VX-445 at a dose of 50, 100, or 200 mg orally once daily in triple combination with tezacaftor (100 mg per day) and ivacaftor (150 mg every 12 hours) -or a triple placebo control. Patients with the Phe508del-Phe508del genotype received a 4-week run-in with tezacaftor and ivacaftor and were randomly assigned to receive 4 weeks of treatment with either VX-445 (200 mg per day orally) plus tezacaftor (100 mg per day) and ivacaftor (150 mg every 12 hours) or matched placebo plus tezacaftor and ivacaftor. In addition, the trial included patients with Phe508del-MF genotypes treated with VX-445 in triple combination with tezacaftor and VX-561, a deuterated form of ivacaftor taken once daily, or triple placebo. For details regarding trial design and oversight, including a description of VX-561, trial participants, and assessments, see the accompanying article on VX-659 by Davies et al.
T h e ne w e ngl a nd jou r na l o f m e dicine and the Supplementary Appendix of this article (pages 7 through 14, Fig. S1 , and Table S1 ).
Clinical Efficacy
Clinical efficacy was evaluated on the basis of the change in forced expiratory volume in 1 second (FEV 1 ) from baseline and a disease-specific healthrelated quality-of-life instrument, the Cystic Fibrosis Questionnaire-Revised (CFQ-R). Each CFQ-R domain is scored on a 100-point scale, with higher scores indicating a lower effect of symptoms on the patient's quality of life. A minimal clinically important difference of 4 points has been determined for the respiratory symptoms domain.
Statistical Analysis
All statistical tests were two-sided and performed at a significance level of 5%. Analyses were performed with the use of SAS software, version 9.4 (SAS Institute). The final analysis included all patients after the last patient visit. Further information on the statistical analysis is available in the accompanying article on VX-659 by Davies et al. 1 and in the Supplementary Appendix of this article.
R esult s
VX-445-Tezacaftor-Ivacaftor In Vitro
The CFTR corrector VX-445 increased expression of mature CFTR protein in bronchial epithelial cells isolated from four donors with Phe508del-MF genotypes and three donors with the Phe508del-Phe508del genotype (Fig. 1A) . The combination of VX-445 and tezacaftor, with or without ivacaftor, increased levels of mature CFTR protein (Fig. 1B) and led to an increase in chloride transport that was greater than that in cells exposed to VX-445 or tezacaftor alone or in untreated cells. The addition of ivacaftor potentiated chloride transport by the mature Phe508del-CFTR protein that VX-445-tezacaftor delivered to the cell surface, resulting in a greater increase in chloride transport than with monotherapy or dual-therapy combinations in human bronchial epithelial cells from Phe508del-MF and Phe508del-Phe508del donors (Fig. 1C) . These in vitro studies provided the molecular and biologic rationale for investigating VX-445-tezacaftor-ivacaftor in patients with cystic fibrosis with Phe508del-MF or Phe508del-Phe508del genotypes.
VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis
Patient Population
A total of 123 patients with cystic fibrosis were enrolled in the trial and underwent randomization, including 95 patients with Phe508del-MF genotypes and 28 patients with the Phe508del-Phe508del genotype. Among these patients, 122 received at least one dose of the trial regimen: 74 received VX-445-tezacaftor-ivacaftor, 21 received VX-445-tezacaftor-VX-561, and 27 received a control regimen (triple placebo or placebo plus tezacaftor-ivacaftor); 119 patients completed 4 weeks of the trial regimen ( Fig. S2 in the Supplementary Appendix). At baseline, age, sex, percentage of predicted FEV 1 , and sweat chloride concentration were well balanced across genotype and intervention groups (P>0.05 for all comparisons) ( Table 1, and Table S2 in the Supplementary Appendix). Baseline CFQ-R scores were as much as 8.5 points lower in the triple placebo group than in the active-treatment groups among patients with Phe508del-MF genotypes who received VX-445-tezacaftor-ivacaftor. Baseline demographic and clinical characteristics and results for patients with Phe508del-MF genotypes who received VX-445-tezacaftor-VX-561 are described on pages 34 through 47 and in Table S3 in the Supplementary Appendix.
Safety
A total of 68 of 74 patients who received VX-445-tezacaftor-ivacaftor (92%) reported at least one adverse event, as did 12 patients who received triple placebo (100%) and 5 of 7 patients who received tezacaftor-ivacaftor (71%) (see Table 2 ; and Table S4 in the Supplementary Appendix, which provides a complete summary of all adverse events). Among the 68 patients who received VX-445-tezacaftor-ivacaftor and had an adverse event, 36 (53%) had mild events, 29 (43%) had moderate events, and 3 (4%) had severe events. Serious adverse events occurred in 3 patients (4%) in the VX-445-tezacaftor-ivacaftor group, 2 patients (17%) in the triple placebo group, and 1 patient (14%) in the tezacaftor-ivacaftor group. Five serious adverse events occurred in 3 patients receiving VX-445-tezacaftor-ivacaftor, with two events of infective pulmonary exacerbation of cystic fibrosis and two events of distal intestinal obstruction syndrome; 1 patient who had both distal intestinal obstruction syndrome
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and infective pulmonary exacerbation of cystic fibrosis also had a serious adverse event of jugular venous thrombosis. No deaths occurred during the trial. Three patients in the VX-445-tezacaftor-ivacaftor group and 1 patient in the control group discontinued treatment because of adverse events. Adverse events leading to discontinuation in patients receiving VX-445-tezacaftor-ivacaftor included rash, elevated bilirubin level, and chest pain, each of which occurred in a different patient. Administration of VX-445-tezacaftor-ivacaftor was interrupted in 3 patients owing to adverse events, which included elevated levels of aspartate aminotransferase, alanine aminotransferase, and creatine kinase in addition to myopathy (all in the same patient) and an elevated bilirubin level and constipation (each of which occurred in a different patient).
The most common adverse events (i.e., incidence >10%) that occurred in patients receiving VX-445-tezacaftor-ivacaftor were cough, increased sputum production, infective pulmonary exacerbation of cystic fibrosis, hemoptysis, and pyrexia ( Table 2 ). The incidence of abnormal results on tests of liver function, defined as a result greater than three times the upper limit of the normal range for levels of aspartate aminotransferase or alanine aminotransferase, was 8%. The incidence of elevation of bilirubin levels greater than two times the upper limit of normal was 3% (see Table S5 in the Supplementary Appendix). No evidence of acute bronchoconstriction was observed after dosing with VX-445-tezacaftor-ivacaftor. The safety profile of VX-445-tezacaftor-VX-561 was similar to that of VX-445-tezacaftor-ivacaftor (Tables S6 and S7 
Efficacy
Treatment with VX-445-tezacaftor-ivacaftor resulted in significant improvements over baseline in the percentage of predicted FEV 1 in patients with Phe508del-MF genotypes and those with the Phe508del-Phe508del genotype for all administered doses (see Table 3 for the absolute change in the percentage of predicted FEV 1 and Table S8 in the Supplementary Appendix for the relative change in percentage of predicted FEV 1 and the absolute and relative changes in raw FEV 1 ). In the VX-445-tezacaftor-ivacaftor groups, improvements in the percentage of predicted FEV 1 were observed at the first assessment on day 15 and maintained at day 29 ( Fig. 2A and  2B) . Consistent with the magnitude of improvement in percentage of predicted FEV 1 , improvements were also observed in both genotype groups for the secondary end points of sweat chloride concentration, an in vivo measure of CFTR function, and CFQ-R respiratory domain score ( Fig. 2A and 2B and Table 3 ). Improvement in CFQ-R respiratory domain score at day 29 was observed, with adjustment (Table S9 in the Supplementary Appendix) or without adjustment for baseline CFQ-R score (Table 3) . Individual patient data for the absolute change from baseline in percentage of predicted FEV 1 and sweat chloride concentration at day 29 are included in Figure S3 in the Supplementary Appendix. Patients with Phe508del-MF genotypes who received VX-445-tezacaftor-VX-561 had similar improvements in efficacy outcomes (Table S10 and Fig. S4 in the Supplementary Appendix).
Discussion
In this proof-of-concept clinical trial involving patients with cystic fibrosis with one or two Phe508del alleles, treatment with VX-445-tezacaftor-ivacaftor significantly increased the percentage of predicted FEV 1 , by up to 13.8 percentage points in patients with Phe508del-MF genotypes and up to 11.0 percentage points in patients with the Phe508del-Phe508del genotype who were already receiving tezacaftor-ivacaftor. As has been the case in previous trials of effective CFTR modulators, 3-7 the effect was noted at the time of the initial measurement after the start of treatment and was maintained throughout the trial. Increases in percentage of predicted FEV 1 were accompanied by decreases in sweat chloride concentrations, indicating improved CFTR function, and in CFQ-R respiratory domain score.
VX-445 triple combination therapy had an acceptable adverse-event profile in both patient populations studied. Among the 92% of patients who had an adverse event, 97% had events that were mild or moderate in severity, and the trial drug was interrupted or discontinued as a result of adverse events in 8% of patients. The safety profile of VX-445 triple combination therapy was Tezacaftor-ivacaftor (TEZ-IVA) was administered at a dose of 100 mg of TEZ once daily and 150 mg of IVA every 12 hours. FEV 1 denotes forced expiratory volume in 1 second. † Baseline characteristics of the patients were assessed after a 4-week run-in with TEZ-IVA. ‡ Scores on the CFQ-R range from 0 to 100, with higher scores indicating a higher patient-reported quality of life regarding respiratory status and a minimal clinically important difference of 4 points. 
number of patients (percent)
Any adverse event †
12 (100) 10 (100) 21 (96) 18 (86) 5 (71) 19 (90) 68 (92) Maximum severity of adverse event ‡ Mild 5 (42) 5 (50) 8 (38) 13 (72) 2 (40) 10 (53) 36 ( 12 (57) 5 (28) 2 (40) 8 (42) 29 ( 1 (5) 3 (4) Adverse events occurring in ≥10% of patients who received VX-445-TEZ-IVA Cough 1 (8) 4 (40) 5 (23) 7 (33) 1 (14) 7 (33) 23 ( 5 (23) 2 (10) 1 (14) 5 (24) 15 ( 1 (5) 1 (14) 3 (14) 9 (12) * Shown are patients with Phe508del-minimal function or Phe508del-Phe508del genotypes who received VX-445. † A patient with multiple events within a category was counted only once in that category. ‡ No events were considered life-threatening. The denominator is the number of patients with at least one adverse event.
T h e ne w e ngl a nd jou r na l o f m e dicine similar to that observed for the related combination of VX-659, tezacaftor, and ivacaftor, 1 a finding that supports further development of both combinations in phase 3 trials.
The efficacy predicted from in vitro results translated into clinical effects of VX-445-tezacaftor-ivacaftor CFTR modulation in patients with one or two Phe508del alleles, both in magnitude and concept. As anticipated on the basis of complementary mechanisms of action, the chloride transport response with VX-445-tezacaftorivacaftor was larger than that with dual-therapy regimens. The additive effects of VX-445-tezacaftor-ivacaftor in vitro were mirrored in the clinical response seen in patients with Phe508del-MF or Phe508del-Phe508del genotypes.
The data presented here provide in vitro and early in vivo evidence for the use of VX-445 triple combination regimens for the treatment of patients with cystic fibrosis with at least one † Shown is the within-group P value for the comparison with baseline. ‡ The widths of the confidence intervals have not been adjusted for multiple comparisons, and the intervals should not be used to infer definitive treatment effects. § CFQ-R respiratory domain scores were not adjusted for baseline score; a prespecified analysis with adjustment for baseline CFQ-R respiratory domain score is presented in Table S9 in the Supplementary Appendix. sults support the hypothesis that targeting the Phe508del CFTR mutation with a combination of two correctors and a potentiator can lead to effective CFTR function in patients with these forms of cystic fibrosis. Both the VX-445 and VX-659 triple combinations improved lung function (absolute increase in percentage of predicted FEV 1 ) in patients with Phe508del-MF genotypes who had not previously been treated with CFTR modulators, and in patients with the Phe508del-Phe508del genotype, who had previously received treatment with tezacaftor-ivacaftor. 1 Lung function was improved by a magnitude similar to that achieved with the CFTR modulator ivacaftor in patients with gating mutations, in whom treatment has been disease modifying. 3 In these phase 2 trials with 4-week treatment periods, no dose-limiting side effects or toxic effects were noted. Phase 3 studies are under way (ClinicalTrials.gov numbers, NCT03447249, NCT03460990, NCT03447262, NCT03525444, NCT03525548, and NCT03525574) to establish their full safety profiles and confirm efficacy results in larger patient groups. Overall, the results presented here and in the companion report 1 establish proof of concept that high levels of CFTR modulation can be achieved with triple combination CFTR modulator regimens consisting of next-generation CFTR corrector VX-445 or VX-659, the first-generation CFTR corrector tezacaftor, and the CFTR potentiator ivacaftor in patients with at least one Phe508del allele. These paired reports represent two independent investigations that support the translation of in vitro findings from an airway epithelial-cell model to clinical results. The results of these studies provide support for further development of both CFTR modulator combinations, which have the potential to treat the underlying cause of cystic fibrosis in approximately 90% of patients with the disease.
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